FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported ... while its business making ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck & Company ( (MRK)) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its investors. Merck & Company, also known as MSD outside the United ...

(RTTNews) - Merck & Co Inc. (MRK) released earnings for third quarter that decreased from last year The company's bottom line totaled $3.157 billion, or $1.24 per share. This compares with $4.745 ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

Merck KGaA's shares jumped after the German ... The life-sciences and chemicals group lifted its mid-term outlook for its electronics business, which supplies materials to the chip and display ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...